{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:01:20Z","timestamp":1790197280691,"version":"4.1.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100020950","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["112-2314-B-442-003"],"award-info":[{"award-number":["112-2314-B-442-003"]}],"id":[{"id":"10.13039\/501100020950","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020950","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["113-2314-B-442-002"],"award-info":[{"award-number":["113-2314-B-442-002"]}],"id":[{"id":"10.13039\/501100020950","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020950","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["114-231"],"award-info":[{"award-number":["114-231"]}],"id":[{"id":"10.13039\/501100020950","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"DOI":"10.1245\/s10434-026-20602-7","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:10:25Z","timestamp":1790194225000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ferroptosis at the Metabolic\u2013Immune Interface in Metastatic Castration-Resistant Prostate Cancer: Mechanistic Evidence, Translational Gaps, and Combination Strategies"],"prefix":"10.1245","author":[{"given":"Chun-Chi","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Jen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Yu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"issue":"3","key":"20602_CR1","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.eururo.2024.11.013","volume":"87","author":"EJ Schafer","year":"2025","unstructured":"Schafer EJ, Laversanne M, Sung H, et al. Recent patterns and trends in global prostate cancer incidence and mortality: an update. Eur Urol. 2025;87(3):302\u201313. https:\/\/doi.org\/10.1016\/j.eururo.2024.11.013.","journal-title":"Eur Urol."},{"issue":"11","key":"20602_CR2","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","volume":"371","author":"ES Antonarakis","year":"2014","unstructured":"Antonarakis ES, Lu C, Wang H, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014;371(11):1028\u201338. https:\/\/doi.org\/10.1056\/NEJMoa1315815.","journal-title":"N Engl J Med."},{"issue":"14","key":"20602_CR3","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1200\/JCO-24-01283","volume":"43","author":"DP Petrylak","year":"2025","unstructured":"Petrylak DP, Ratta R, Matsubara N, et al. Pembrolizumab plus docetaxel versus docetaxel for previously treated metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-921 trial. J Clin Oncol. 2025;43(14):1638\u201349. https:\/\/doi.org\/10.1200\/JCO-24-01283.","journal-title":"J Clin Oncol."},{"issue":"5","key":"20602_CR4","doi-asserted-by":"publisher","first-page":"102384","DOI":"10.1016\/j.clgc.2025.102384","volume":"23","author":"N Lambert","year":"2025","unstructured":"Lambert N, Moore C, Klavon J, et al. Clinical outcomes of patients with metastatic prostate cancer with microsatellite instability treated with pembrolizumab. Clin Genitourin Cancer. 2025;23(5):102384. https:\/\/doi.org\/10.1016\/j.clgc.2025.102384.","journal-title":"Clin Genitourin Cancer."},{"issue":"5","key":"20602_CR5","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1001294.","journal-title":"N Engl J Med."},{"issue":"12","key":"20602_CR6","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385(12):1091\u2013103. https:\/\/doi.org\/10.1056\/NEJMoa2107322.","journal-title":"N Engl J Med."},{"issue":"10276","key":"20602_CR7","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","volume":"397","author":"MS Hofman","year":"2021","unstructured":"Hofman MS, Emmett L, Sandhu S, et al. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397(10276):797\u2013804. https:\/\/doi.org\/10.1016\/S0140-6736(21)00237-3.","journal-title":"Lancet."},{"issue":"11","key":"20602_CR8","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1016\/S1470-2045(23)00451-5","volume":"24","author":"R Aggarwal","year":"2023","unstructured":"Aggarwal R, Starzinski S, de Kouchkovsky I, et al. Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial. Lancet Oncol. 2023;24(11):1266\u201376. https:\/\/doi.org\/10.1016\/S1470-2045(23)00451-5.","journal-title":"Lancet Oncol."},{"issue":"1","key":"20602_CR9","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s12967-025-06180-4","volume":"23","author":"H Yang","year":"2025","unstructured":"Yang H, Zhang X, Jia Z, et al. Targeting ferroptosis in prostate cancer management: molecular mechanisms, multidisciplinary strategies and translational perspectives. J Transl Med. 2025;23(1):166. https:\/\/doi.org\/10.1186\/s12967-025-06180-4.","journal-title":"J Transl Med."},{"issue":"1","key":"20602_CR10","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s00109-026-02641-5","volume":"104","author":"Z Wang","year":"2026","unstructured":"Wang Z, Chen G, Liu Z. Integrated regulation of ferroptosis in prostate cancer covering mechanisms, resistance, and translational opportunities. J Mol Med (Berl). 2026;104(1):40. https:\/\/doi.org\/10.1007\/s00109-026-02641-5.","journal-title":"J Mol Med (Berl)."},{"issue":"1","key":"20602_CR11","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s41391-024-00933-w","volume":"29","author":"H Chen","year":"2026","unstructured":"Chen H, Lyu F, Gao X. Advances in ferroptosis for castration-resistant prostate cancer treatment: novel drug targets and combination therapy strategies. Prostate Cancer Prostatic Dis. 2026;29(1):36\u201346. https:\/\/doi.org\/10.1038\/s41391-024-00933-w.","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"5","key":"20602_CR12","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","volume":"149","author":"SJ Dixon","year":"2012","unstructured":"Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060\u201372. https:\/\/doi.org\/10.1016\/j.cell.2012.03.042.","journal-title":"Cell."},{"issue":"1\u20132","key":"20602_CR13","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.cell.2013.12.010","volume":"156","author":"WS Yang","year":"2014","unstructured":"Yang WS, SriRamaratnam R, Welsch ME, et al. Regulation of ferroptotic cancer cell death by GPX4. Cell. 2014;156(1\u20132):317\u201331. https:\/\/doi.org\/10.1016\/j.cell.2013.12.010.","journal-title":"Cell."},{"issue":"7784","key":"20602_CR14","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/s41586-019-1705-2","volume":"575","author":"K Bersuker","year":"2019","unstructured":"Bersuker K, Hendricks JM, Li Z, et al. The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. Nature. 2019;575(7784):688\u201392. https:\/\/doi.org\/10.1038\/s41586-019-1705-2.","journal-title":"Nature."},{"issue":"1","key":"20602_CR15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1021\/acscentsci.9b01063","volume":"6","author":"VAN Kraft","year":"2020","unstructured":"Kraft VAN, Bezjian CT, Pfeiffer S, et al. GTP cyclohydrolase 1\/tetrahydrobiopterin counteract ferroptosis through lipid remodeling. ACS Cent Sci. 2020;6(1):41\u201353. https:\/\/doi.org\/10.1021\/acscentsci.9b01063.","journal-title":"ACS Cent Sci."},{"issue":"7860","key":"20602_CR16","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41586-021-03539-7","volume":"593","author":"C Mao","year":"2021","unstructured":"Mao C, Liu X, Zhang Y, et al. DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer. Nature. 2021;593(7860):586\u201390. https:\/\/doi.org\/10.1038\/s41586-021-03539-7.","journal-title":"Nature."},{"issue":"1","key":"20602_CR17","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nchembio.2239","volume":"13","author":"S Doll","year":"2017","unstructured":"Doll S, Proneth B, Tyurina YY, et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat Chem Biol. 2017;13(1):91\u20138. https:\/\/doi.org\/10.1038\/nchembio.2239.","journal-title":"Nat Chem Biol."},{"issue":"9","key":"20602_CR18","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1038\/s41556-024-01360-8","volume":"26","author":"E Dai","year":"2024","unstructured":"Dai E, Chen X, Linkermann A, et al. A guideline on the molecular ecosystem regulating ferroptosis. Nat Cell Biol. 2024;26(9):1447\u201357. https:\/\/doi.org\/10.1038\/s41556-024-01360-8.","journal-title":"Nat Cell Biol."},{"issue":"19","key":"20602_CR19","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1158\/0008-5472.CAN-23-0285","volume":"83","author":"R Sun","year":"2023","unstructured":"Sun R, Yan B, Li H, et al. Androgen receptor variants confer castration resistance in prostate cancer by counteracting antiandrogen-induced ferroptosis. Cancer Res. 2023;83(19):3192\u2013204. https:\/\/doi.org\/10.1158\/0008-5472.CAN-23-0285.","journal-title":"Cancer Res."},{"key":"20602_CR20","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40170-020-00217-6","volume":"8","author":"KD Tousignant","year":"2020","unstructured":"Tousignant KD, Rockstroh A, Poad BLJ, et al. Therapy-induced lipid uptake and remodeling underpin ferroptosis hypersensitivity in prostate cancer. Cancer Metab. 2020;8:11. https:\/\/doi.org\/10.1186\/s40170-020-00217-6.","journal-title":"Cancer Metab."},{"issue":"1","key":"20602_CR21","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41419-025-07809-4","volume":"16","author":"M Tang","year":"2025","unstructured":"Tang M, Xue L, Wang B, et al. SLC7A11 upregulation via AR and NEDD4L ubiquitination contributes to ferroptosis inhibition and enzalutamide resistance in castration-resistant prostate cancer. Cell Death Dis. 2025;16(1):591. https:\/\/doi.org\/10.1038\/s41419-025-07809-4.","journal-title":"Cell Death Dis."},{"issue":"1","key":"20602_CR22","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1038\/s41467-020-16126-7","volume":"11","author":"A Blomme","year":"2020","unstructured":"Blomme A, Ford CA, Mui E, et al. 2,4-dienoyl-CoA reductase regulates lipid homeostasis in treatment-resistant prostate cancer. Nat Commun. 2020;11(1):2508. https:\/\/doi.org\/10.1038\/s41467-020-16126-7.","journal-title":"Nat Commun."},{"issue":"10","key":"20602_CR23","doi-asserted-by":"publisher","first-page":"e166647","DOI":"10.1172\/JCI166647","volume":"133","author":"ME Wang","year":"2023","unstructured":"Wang ME, Chen J, Lu Y, et al. RB1-deficient prostate tumor growth and metastasis are vulnerable to ferroptosis induction via the E2F\/ACSL4 axis. J Clin Invest. 2023;133(10):e166647. https:\/\/doi.org\/10.1172\/JCI166647.","journal-title":"J Clin Invest."},{"issue":"5","key":"20602_CR24","doi-asserted-by":"publisher","first-page":"e1678","DOI":"10.1002\/ctm2.1678","volume":"14","author":"H Zhang","year":"2024","unstructured":"Zhang H, Zhou Y, Feng Y, et al. Cyclin-dependent kinase 12 deficiency reprogrammes cellular metabolism to alleviate ferroptosis potential and promote the progression of castration-resistant prostate cancer. Clin Transl Med. 2024;14(5):e1678. https:\/\/doi.org\/10.1002\/ctm2.1678.","journal-title":"Clin Transl Med."},{"issue":"1","key":"20602_CR25","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41392-025-02170-6","volume":"10","author":"S Ma","year":"2025","unstructured":"Ma S, Wang Z, Xiong Z, et al. Enhancer transcription profiling reveals an enhancer RNA-driven ferroptosis and new therapeutic opportunities in prostate cancer. Signal Transduct Target Ther. 2025;10(1):87. https:\/\/doi.org\/10.1038\/s41392-025-02170-6.","journal-title":"Signal Transduct Target Ther."},{"issue":"1","key":"20602_CR26","doi-asserted-by":"publisher","first-page":"e14077","DOI":"10.1002\/advs.202514077","volume":"13","author":"S Shao","year":"2026","unstructured":"Shao S, Li W, Hong Y, et al. ZDHHC2-dependent palmitoylation dictates ferroptosis and castration sensitivity in prostate cancer via controlling ACSL4 degradation and lipid peroxidation. Adv Sci (Weinh). 2026;13(1):e14077. https:\/\/doi.org\/10.1002\/advs.202514077.","journal-title":"Adv Sci (Weinh)."},{"issue":"1","key":"20602_CR27","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41419-026-08746-6","volume":"17","author":"X Zhu","year":"2026","unstructured":"Zhu X, Wen Z, Wu J, et al. Aberrant activation of epigenetic BRD9-DGAT1 axis promotes lipid droplets deposition and ferroptosis resistance in YAP-high prostate cancer. Cell Death Dis. 2026;17(1):477. https:\/\/doi.org\/10.1038\/s41419-026-08746-6.","journal-title":"Cell Death Dis."},{"issue":"1","key":"20602_CR28","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/s41419-026-08906-8","volume":"17","author":"Y Zhou","year":"2026","unstructured":"Zhou Y, He J, Zhang H, et al. Ferroptosis vulnerability of enzalutamide resistant prostate cancer conferred by ACSL4 overexpression and GPX4 antagonism. Cell Death Dis. 2026;17(1):665. https:\/\/doi.org\/10.1038\/s41419-026-08906-8.","journal-title":"Cell Death Dis."},{"issue":"2","key":"20602_CR29","doi-asserted-by":"publisher","first-page":"e001369","DOI":"10.1136\/jitc-2020-001369","volume":"8","author":"I Efimova","year":"2020","unstructured":"Efimova I, Catanzaro E, Van der Meeren L, et al. Vaccination with early ferroptotic cancer cells induces efficient antitumor immunity. J Immunother Cancer. 2020;8(2):e001369. https:\/\/doi.org\/10.1136\/jitc-2020-001369.","journal-title":"J Immunother Cancer."},{"issue":"1","key":"20602_CR30","doi-asserted-by":"publisher","first-page":"3676","DOI":"10.1038\/s41467-022-31218-2","volume":"13","author":"B Wiernicki","year":"2022","unstructured":"Wiernicki B, Maschalidi S, Pinney J, et al. Cancer cells dying from ferroptosis impede dendritic cell-mediated anti-tumor immunity. Nat Commun. 2022;13(1):3676. https:\/\/doi.org\/10.1038\/s41467-022-31218-2.","journal-title":"Nat Commun."},{"issue":"4","key":"20602_CR31","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.ccell.2022.02.003","volume":"40","author":"P Liao","year":"2022","unstructured":"Liao P, Wang W, Wang W, et al. CD8+ T cells and fatty acids orchestrate tumor ferroptosis and immunity via ACSL4. Cancer Cell. 2022;40(4):365-378.e6. https:\/\/doi.org\/10.1016\/j.ccell.2022.02.003.","journal-title":"Cancer Cell."},{"issue":"2","key":"20602_CR32","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.apsb.2021.07.016","volume":"12","author":"X Zhou","year":"2022","unstructured":"Zhou X, Zou L, Liao H, et al. Abrogation of HnRNP L enhances anti-PD-1 therapy efficacy via diminishing PD-L1 and promoting CD8+ T cell-mediated ferroptosis in castration-resistant prostate cancer. Acta Pharm Sin B. 2022;12(2):692\u2013707. https:\/\/doi.org\/10.1016\/j.apsb.2021.07.016.","journal-title":"Acta Pharm Sin B."},{"key":"20602_CR33","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-25-4954","author":"NA Siddiqui","year":"2026","unstructured":"Siddiqui NA, Zhang L, DeLeon G, et al. Reprogramming of TLR-ferroptosis signaling and immunometabolic pathways overcomes myeloid suppression to improve checkpoint blockade in prostate cancer. Cancer Res. 2026. https:\/\/doi.org\/10.1158\/0008-5472.CAN-25-4954.","journal-title":"Cancer Res."},{"key":"20602_CR34","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.34133\/research.1331","volume":"9","author":"L Wang","year":"2026","unstructured":"Wang L, He H, Lei C, et al. Combined dihydroartemisinin and eupatilin suppress prostate cancer through AR-associated ferroptosis and modulation of macrophage-tumor crosstalk. Research (Wash D C). 2026;9:1331. https:\/\/doi.org\/10.34133\/research.1331.","journal-title":"Research (Wash D C)."},{"issue":"5","key":"20602_CR35","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.cmet.2021.02.015","volume":"33","author":"X Ma","year":"2021","unstructured":"Ma X, Xiao L, Liu L, et al. CD36-mediated ferroptosis dampens intratumoral CD8+ T cell effector function and impairs their antitumor ability. Cell Metab. 2021;33(5):1001-1012.e5. https:\/\/doi.org\/10.1016\/j.cmet.2021.02.015.","journal-title":"Cell Metab."},{"issue":"7","key":"20602_CR36","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1016\/j.immuni.2021.05.003","volume":"54","author":"S Xu","year":"2021","unstructured":"Xu S, Chaudhary O, Rodr\u00edguez-Morales P, et al. Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8+ T cells in tumors. Immunity. 2021;54(7):1561-1577.e7. https:\/\/doi.org\/10.1016\/j.immuni.2021.05.003.","journal-title":"Immunity."},{"issue":"9","key":"20602_CR37","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1038\/s41590-021-00996-0","volume":"22","author":"Y Yao","year":"2021","unstructured":"Yao Y, Chen Z, Zhang H, et al. Selenium-GPX4 axis protects follicular helper T cells from ferroptosis. Nat Immunol. 2021;22(9):1127\u201339. https:\/\/doi.org\/10.1038\/s41590-021-00996-0.","journal-title":"Nat Immunol."},{"issue":"11","key":"20602_CR38","doi-asserted-by":"publisher","first-page":"109235","DOI":"10.1016\/j.celrep.2021.109235","volume":"35","author":"C Xu","year":"2021","unstructured":"Xu C, Sun S, Johnson T, et al. The glutathione peroxidase Gpx4 prevents lipid peroxidation and ferroptosis to sustain Treg cell activation and suppression of antitumor immunity. Cell Rep. 2021;35(11):109235. https:\/\/doi.org\/10.1016\/j.celrep.2021.109235.","journal-title":"Cell Rep."},{"key":"20602_CR39","doi-asserted-by":"publisher","first-page":"218243","DOI":"10.1016\/j.canlet.2026.218243","volume":"639","author":"Y Zhang","year":"2026","unstructured":"Zhang Y, Zhao H, Xu P, et al. The Zeb1\/system Xc\u2212 axis safeguards iron-loaded cancer-associated fibroblasts against ferroptosis and promotes immunosuppression in prostate cancer. Cancer Lett. 2026;639:218243. https:\/\/doi.org\/10.1016\/j.canlet.2026.218243.","journal-title":"Cancer Lett."},{"issue":"1","key":"20602_CR40","doi-asserted-by":"publisher","first-page":"e000337","DOI":"10.1136\/jitc-2019-000337","volume":"8","author":"L Galluzzi","year":"2020","unstructured":"Galluzzi L, Vitale I, Warren S, et al. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. J Immunother Cancer. 2020;8(1):e000337. https:\/\/doi.org\/10.1136\/jitc-2019-000337.","journal-title":"J Immunother Cancer."},{"issue":"12","key":"20602_CR41","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1038\/s43018-022-00468-w","volume":"3","author":"N Samson","year":"2022","unstructured":"Samson N, Ablasser A. The cGAS-STING pathway and cancer. Nat Cancer. 2022;3(12):1452\u201363. https:\/\/doi.org\/10.1038\/s43018-022-00468-w.","journal-title":"Nat Cancer."},{"issue":"23","key":"20602_CR42","doi-asserted-by":"publisher","first-page":"5948","DOI":"10.1158\/0008-5472.CAN-20-3607","volume":"81","author":"R Kumar","year":"2021","unstructured":"Kumar R, Mendonca J, Owoyemi O, et al. Supraphysiologic testosterone induces ferroptosis and activates immune pathways through nucleophagy in prostate cancer. Cancer Res. 2021;81(23):5948\u201362. https:\/\/doi.org\/10.1158\/0008-5472.CAN-20-3607.","journal-title":"Cancer Res."},{"issue":"6","key":"20602_CR43","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1158\/0008-5472.CAN-20-3477","volume":"81","author":"A Ghoochani","year":"2021","unstructured":"Ghoochani A, Hsu EC, Aslan M, et al. Ferroptosis inducers are a novel therapeutic approach for advanced prostate cancer. Cancer Res. 2021;81(6):1583\u201394. https:\/\/doi.org\/10.1158\/0008-5472.CAN-20-3477.","journal-title":"Cancer Res."},{"issue":"720","key":"20602_CR44","doi-asserted-by":"publisher","first-page":"eadg3049","DOI":"10.1126\/scitranslmed.adg3049","volume":"15","author":"J Li","year":"2023","unstructured":"Li J, Liu J, Zhou Z, et al. Tumor-specific GPX4 degradation enhances ferroptosis-initiated antitumor immune response in mouse models of pancreatic cancer. Sci Transl Med. 2023;15(720):eadg3049. https:\/\/doi.org\/10.1126\/scitranslmed.adg3049.","journal-title":"Sci Transl Med."},{"issue":"12","key":"20602_CR45","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1158\/2159-8290.CD-19-0338","volume":"9","author":"X Lang","year":"2019","unstructured":"Lang X, Green MD, Wang W, et al. Radiotherapy and immunotherapy promote tumoral lipid oxidation and ferroptosis via synergistic repression of SLC7A11. Cancer Discov. 2019;9(12):1673\u201385. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-0338.","journal-title":"Cancer Discov."},{"key":"20602_CR46","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41392-026-02847-6","volume":"11","author":"T Tsujino","year":"2026","unstructured":"Tsujino T, Yamazaki S, Sakamoto M, et al. A ferroptosis-suppressive state drives resistance to bladder-preserving chemoradiotherapy in muscle-invasive bladder cancer. Signal Transduct Target Ther. 2026;11:299. https:\/\/doi.org\/10.1038\/s41392-026-02847-6.","journal-title":"Signal Transduct Target Ther."},{"issue":"1","key":"20602_CR47","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12951-025-03879-w","volume":"24","author":"Z Hu","year":"2025","unstructured":"Hu Z, Li H, Gan K, et al. Active-targeting biomimetic nanosystem for prostate cancer enhances radiotherapy efficacy by inducing ferroptosis. J Nanobiotechnology. 2025;24(1):9. https:\/\/doi.org\/10.1186\/s12951-025-03879-w.","journal-title":"J Nanobiotechnology."},{"key":"20602_CR48","doi-asserted-by":"publisher","DOI":"10.1111\/cas.70479","author":"J Yang","year":"2026","unstructured":"Yang J, Chen P, Zheng Y, et al. Targeting the NR3C1-ACSL4 Axis triggers ferroptosis to overcome radioresistance in prostate cancer. Cancer Sci. 2026. https:\/\/doi.org\/10.1111\/cas.70479.","journal-title":"Cancer Sci."},{"issue":"9","key":"20602_CR49","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1007\/s00259-023-06255-8","volume":"50","author":"C Kratochwil","year":"2023","unstructured":"Kratochwil C, Fendler WP, Eiber M, et al. Joint EANM\/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging. 2023;50(9):2830\u201345. https:\/\/doi.org\/10.1007\/s00259-023-06255-8.","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"3","key":"20602_CR50","doi-asserted-by":"publisher","first-page":"836","DOI":"10.7150\/thno.101882","volume":"15","author":"A Moses","year":"2025","unstructured":"Moses A, Malek R, Kendirli MT, et al. Monitoring of cancer ferroptosis with [18F]hGTS13, a system xc\u2212 specific radiotracer. Theranostics. 2025;15(3):836\u201349. https:\/\/doi.org\/10.7150\/thno.101882.","journal-title":"Theranostics."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20602-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-20602-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20602-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:10:27Z","timestamp":1790194227000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-20602-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":50,"alternative-id":["20602"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-20602-7","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]},"assertion":[{"value":"21 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interest relevant to this work.","order":1,"name":"Ethics","label":"Disclosure","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"During the preparation of this work, the authors used ChatGPT to assist with manuscript restructuring, language revision, and preliminary organization of evidence. All references, quantitative clinical data, and trial-registry information were independently verified by the authors against the cited sources. Following the use of this tool, the authors reviewed and edited the content as needed and take full responsibility for the final content of the publication. The schematic figures were assembled and edited by the authors using standard vector-graphics software. Artificial intelligence is not listed as an author, and the authors take full responsibility for the accuracy, integrity, and final content of this work.","order":2,"name":"Ethics","label":"Generative AI Disclosure","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}